Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
Capex
A1 A2 A3 A4 A5
REGN
FY2026 Q1
Improving
Regeneron Pharmaceuticals, Inc. earnings call
Buzzberg read
Dupixent growth and margin improvement expected to boost collaboration revenue
Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47.
Buzzberg read Dupixent growth and margin improvement expected to boost collaboration revenue Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47. Read full analysisCollapse analysis
Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47.
- Dupixent global sales grew 31% to $4.9B, with new indications approved.
- ILEA franchise is bifurcating: ILEA-HD +52% YoY, ILEA declining as biosimilars approach.
- Pipeline progress highlighted: positive Phase 3 for C5 siRNA in MG, Phase 3 data for GLP-1/GIP partner, and BLA acceptance for garitosumab.
Revenue$3.6054B-7% QoQ
EPS$9.47-17% QoQ
Gross margin81.43%Reported
Operating margin17.83%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Pipeline
Fianelmab melanoma PFS data expected later this quarter
Regulatory
Eylea HD PFS decision expected this quarter after FDA miss
Show 3 more callouts
Capital Allocation
New $3 billion buyback authorized, with $3.4 billion available
Pipeline
Obesity combo with Praluent positioned as preferred GLP-1
Data
Linazific infectious risk decreases with longer treatment
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $3.6054B | -7% QoQ |
| EPS | $9.47 | -17% QoQ |
| Gross margin | 81.43% | Reported |
| Operating margin | 17.83% | Reported |
| Free cash flow | $0.8483B | -8% QoQ |
| Capex | $0.2306B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Gross margin | FY2026 | 77%–78% | 77.5% | Maintained |
AI, capex & demand read
Management read
Confident
Management struck a confident tone, highlighting strong commercial execution, pipeline progress, and a new share repurchase authorization, while framing challenges like the FDA delay on the pre-filled syringe as near-term issues.
Investment and capacity
Management noted a temporary interruption in bulk manufacturing at its Limerick, Ireland site, which has resumed initial production and is expected to return to full production by the end of the second quarter. GAAP gross margin guidance was lowered to 77%-78% due to related costs, but product availability was not impacted.
all 1 named companies below
Companiesreturns since call
Partners
Partners
Dr. Leonard Schleifer
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue. — This is a significant, durable revenue tailwind for Regeneron from Q3 onwards.
Evidence
“Maybe it'll give me an opportunity to publicly thank Paul Hudson for all the work he did on Dupixent since 2019...”
External signals
Supply-chain alpha · 5returns since call
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue.
Evidence
“We now expect the Sanofi development balance to be fully repaid by the end of the second quarter. As a result, we expect Sanofi collaboration revenue to step up to reflect our full share of collaboration profits starting in the third quart…”
ILEA (Eylea) demand is expected to decline in the mid-to-high teens QoQ in Q2 ahead of new biosimilar launches, while ILEA-HD demand grows ~10% sequentially.
Evidence
“...for ILEA, we anticipate that demand will decline in the mid to high teens in the second quarter ahead of the potential launch of additional biosimilars in the second half of the year coupled with the factors that I highlighted earlier.”
Regeneron has a strategic goal to match up to $200 million in 2026 for patient assistance contributions via Good Days, with Q1 contributions de minimis.
Evidence
“We remain committed to matching up to $200 million in 2026 to support patient access and affordability.”
GAAP gross margin will be negatively impacted in Q2 due to a temporary interruption in bulk manufacturing at Limerick, Ireland, with production resuming to full capacity by end of Q2.
Evidence
“We have now resumed initial production in the facility and expect to resume full production by the end of the second quarter. As a result, we anticipate our GAAP gross margin will continue to be negatively impacted in the second quarter as…”
Regeneron is developing next-gen IL-13 antibodies and is planning an expedited path to approval, seeking to broaden the atopic dermatitis market to include mild patients.
Evidence
“We don't necessarily think about having to exactly replace or work on. We have nearly 50 things in the pipeline, and we're looking forward to bringing as many important ones forward as we can.”
Methodology & coverage
Management-only analysis. All 1 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.